A new biotech born from Jazz Pharmaceuticals' acquisition deal is betting that rare disease genetics can unlock treatments ...

BioMarin has agreed to pay $70 million upfront for Fabry disease therapy from GC Biopharma and Hanmi Pharm. At the center of ...

Astellas secures option to license Audax's IL-12 immuno-oncology candidate in a deal worth up to $1.34 billion.

Hematology research now needs new evidence strategies as targeted therapies create smaller, more specialized patient groups ...

New ICER and PHIL data show drug launch prices soaring while patients, especially on Medicare, struggle to access needed care ...

Dren Bio has closed an oversubscribed $350 million private financing round to advance its lead antibody candidate toward ...

Flagship has merged 3 of its own portfolio companies into a single powerhouse aimed at predicting how drugs will work before ...

A ten-member European consortium led by Exogenus Therapeutics has secured $14.4 million to develop a disease-modifying ...

BMS halted the study earlier this year following three patient deaths in a competitor’s trial.

Intellectual property enforcement in the life sciences sector is evolving rapidly overall, and in no small part due to ...

Accounting leaders from Biogen, Vertex, Akebia and Roivant share how AI boosts efficiency while human review remains ...

Kos Biotechnology invests in Golden Age Health to widen rare disease access in Asia-Pacific.